JP2024515826A5 - - Google Patents
Info
- Publication number
- JP2024515826A5 JP2024515826A5 JP2023566511A JP2023566511A JP2024515826A5 JP 2024515826 A5 JP2024515826 A5 JP 2024515826A5 JP 2023566511 A JP2023566511 A JP 2023566511A JP 2023566511 A JP2023566511 A JP 2023566511A JP 2024515826 A5 JP2024515826 A5 JP 2024515826A5
- Authority
- JP
- Japan
- Prior art keywords
- biodegradable
- implant according
- ophthalmic implant
- compound
- ophthalmic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182559P | 2021-04-30 | 2021-04-30 | |
| US63/182,559 | 2021-04-30 | ||
| US202163287737P | 2021-12-09 | 2021-12-09 | |
| US63/287,737 | 2021-12-09 | ||
| PCT/US2022/027048 WO2022232588A1 (en) | 2021-04-30 | 2022-04-29 | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515826A JP2024515826A (ja) | 2024-04-10 |
| JP2024515826A5 true JP2024515826A5 (enExample) | 2025-05-20 |
Family
ID=83848732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566511A Pending JP2024515826A (ja) | 2021-04-30 | 2022-04-29 | 眼疾患の処置のための薬学的組成物および硝子体内薬物送達システム |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11786510B2 (enExample) |
| EP (1) | EP4329753A4 (enExample) |
| JP (1) | JP2024515826A (enExample) |
| KR (1) | KR20240004643A (enExample) |
| AU (1) | AU2022264036A1 (enExample) |
| BR (1) | BR112023022705A2 (enExample) |
| CA (1) | CA3218251A1 (enExample) |
| IL (1) | IL307997A (enExample) |
| MX (1) | MX2023012723A (enExample) |
| WO (1) | WO2022232588A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4050997A4 (en) | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS |
| CA3218398A1 (en) * | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
| EP4329753A4 (en) * | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
| WO2025137005A1 (en) * | 2023-12-20 | 2025-06-26 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
| WO2025137007A1 (en) * | 2023-12-20 | 2025-06-26 | Perfuse Therapeutics, Inc. | Methods of preparing drug delivery systems for the treatment of ocular diseases |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4282793A (en) | 1992-04-10 | 1993-11-18 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | A microneedle for injection of ocular blood vessels |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| JP2004525890A (ja) | 2001-02-02 | 2004-08-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ピラゾロ［４，３−ｄ］ピリミジンおよびエンドセリンレセプターアンタゴニストまたはチエノピリミジンおよびエンドセリンレセプターアンタゴニストを含む医薬製剤 |
| US20030176356A1 (en) | 2001-04-24 | 2003-09-18 | University Of North Texas Health Science Center | Endothelin antagonists and endothelin-converting enzyme inhibitors for the treatment of glaucoma |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| BRPI1013904A2 (pt) | 2009-04-30 | 2016-07-19 | Univ Midwestern | método e composição para tratar cetoacidose diabética |
| US20110082151A1 (en) | 2009-06-12 | 2011-04-07 | Auspex Pharmaceuticals, Inc. | Sulfonylurea modulators of endothelin receptor |
| KR20130050939A (ko) | 2010-04-12 | 2013-05-16 | 가부시키가이샤 아루떼꾸 우에노 | 망막 질환의 치료 방법 및 이를 위한 안과용 조성물 |
| EP2956096A1 (en) | 2013-02-15 | 2015-12-23 | Allergan, Inc. | Sustained drug delivery implant |
| PT3062775T (pt) | 2013-10-31 | 2018-03-06 | Allergan Inc | Implantes intraoculares contendo prostamida e métodos para a sua utilização |
| MX390909B (es) | 2013-12-19 | 2025-03-21 | Tassos Georgiou | Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. |
| ES2584534B1 (es) | 2015-03-27 | 2017-03-13 | Retinset, S.L. | Formulación tópica oftálmica de bosentan |
| CN107921036A (zh) * | 2015-05-29 | 2018-04-17 | 优势医疗公司 | 用于减少视力丧失的组合物和方法 |
| CN108883070A (zh) | 2015-07-23 | 2018-11-23 | 爱瑞制药公司 | 用于治疗眼病的玻璃体内药物递送系统 |
| WO2017217967A1 (en) | 2016-06-13 | 2017-12-21 | Noveome Biotherapeutics, Inc. | Novel methods for delivering therapeutic agents to the eye via nasal passages |
| WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| EP3642214A2 (en) | 2017-06-19 | 2020-04-29 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| JP2020528082A (ja) * | 2017-07-17 | 2020-09-17 | ロイズマン，キース | 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達 |
| WO2019210194A1 (en) | 2018-04-26 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Pegylated compositions for ocular use, and methods thereof |
| KR20210135560A (ko) | 2019-03-05 | 2021-11-15 | 에어리 파마슈티컬즈, 인코포레이티드 | 안구 질환 또는 장애를 치료하는 약학 조성물 |
| EP4050997A4 (en) | 2019-10-30 | 2022-11-30 | Perfuse Therapeutics, Inc. | TREATMENT OF EYE DISEASES USING ENDOTHELIN RECEPTOR ANTAGONISTS |
| CA3168810A1 (en) | 2020-02-06 | 2021-08-12 | Perfuse Therapeutics, Inc. | Compositions for treatment of ocular diseases |
| EP4329753A4 (en) * | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
| CA3218398A1 (en) * | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Treatment of ocular diseases using endothelin receptor antagonists |
-
2022
- 2022-04-29 EP EP22796857.5A patent/EP4329753A4/en active Pending
- 2022-04-29 MX MX2023012723A patent/MX2023012723A/es unknown
- 2022-04-29 AU AU2022264036A patent/AU2022264036A1/en active Pending
- 2022-04-29 KR KR1020237040742A patent/KR20240004643A/ko active Pending
- 2022-04-29 WO PCT/US2022/027048 patent/WO2022232588A1/en not_active Ceased
- 2022-04-29 IL IL307997A patent/IL307997A/en unknown
- 2022-04-29 BR BR112023022705A patent/BR112023022705A2/pt unknown
- 2022-04-29 JP JP2023566511A patent/JP2024515826A/ja active Pending
- 2022-04-29 CA CA3218251A patent/CA3218251A1/en active Pending
- 2022-11-30 US US18/060,503 patent/US11786510B2/en active Active
-
2023
- 2023-09-07 US US18/463,102 patent/US20230414577A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024515826A5 (enExample) | ||
| US20230172842A1 (en) | Sustained drug delivery implant | |
| AU2015257651B2 (en) | Compounds for treating ophthalmic diseases and disorders | |
| RU2532333C2 (ru) | Внутриглазные системы доставки лекарственного средства с замедленным высвобождением и способы лечения глазных заболеваний | |
| CN103002884B (zh) | 用前房内比马前列素植入物的眼内压降低 | |
| CN107184544A (zh) | 前房内持续释放治疗药植入物 | |
| JP2014014694A (ja) | 血管拡張薬を含有する持続放出性眼内インプラント | |
| WO2014066658A1 (en) | Ketorolac-containing sustained release drug delivery systems | |
| JP6407145B2 (ja) | 網脈絡膜障害の抑制剤 | |
| TW202345803A (zh) | 由投予眼部藥物遞送插入物預防老年黃斑部病變之方法 | |
| WO2020242264A1 (en) | A composition for treating eye diseases | |
| HK40118703A (zh) | 治疗湿性年龄相关性黄斑变性的方法 | |
| HK40118700A (zh) | 通过施用眼部药物递送插入物预防年龄相关性黄斑变性的方法 | |
| CN118891040A (zh) | 治疗湿性年龄相关性黄斑变性的方法 | |
| WO2024124411A1 (zh) | 萘脲类化合物在制备治疗翼状胬肉的药物中的应用 | |
| HK40092417A (zh) | 用於治疗眼科疾病和障碍的化合物 | |
| JP2009544740A5 (enExample) | ||
| HK1183436B (zh) | 用前房内比马前列素植入物的眼内压降低 | |
| HK1183436A (en) | Intraocular pressure reduction with intracameral bimatoprost implants | |
| WO2004037246A1 (ja) | 神経線維再生促進剤 |